Literature DB >> 4553640

Human brain monoamine oxidase: multiple forms and selective inhibitors.

M B Youdim, G G Collins, M Sandler, A B Bevan Jones, C M Pare, W J Nicholson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4553640     DOI： 10.1038/236225b0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  24 in total

1.  The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.

Authors:  W Birkmayer; P Riederer; M B Youdim; W Linauer
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

Review 2.  The modern management of Parkinson's disease.

Authors:  N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

3.  Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.

Authors:  A R Green; B D Mitchell; A F Tordoff; M B Youdim
Journal:  Br J Pharmacol       Date:  1977-07       Impact factor: 8.739

4.  Quantum-chemical approach to determining the high potency of clorgyline as an irreversible acetylenic monoamine oxidase inhibitor.

Authors:  Matic Pavlin; Janez Mavri; Matej Repič; Robert Vianello
Journal:  J Neural Transm (Vienna)       Date:  2013-04-02       Impact factor: 3.575

5.  New look at monoamine oxidase inhibitors. The new biochemical background.

Authors:  M Sandler
Journal:  Proc R Soc Med       Date:  1973-09

6.  Early effects of monoamine oxidase inhibitors on dopamine metabolism and monoamine oxidase activity in the neostriatum of the rat.

Authors:  F Javoy; M B Youdim; Y Agid; J Glowinski
Journal:  J Neural Transm       Date:  1973       Impact factor: 3.575

7.  Long term treatment with L-deprenyl.

Authors:  W Birkmayer
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

8.  Overview of present day treatment of Parkinson's disease.

Authors:  M D Yahr
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

Review 9.  The role of rasagiline in the treatment of Parkinson's disease.

Authors:  Julie Leegwater-Kim; Elena Bortan
Journal:  Clin Interv Aging       Date:  2010-05-25       Impact factor: 4.458

Review 10.  Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.

Authors:  M B Youdim; P Riederer
Journal:  J Neural Transm Gen Sect       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.